Selected Publications

Angst J., Scharfetter C, Stassen HH: Classification of Schizoaffective Patients by Multidimensional Scaling and Cluster Analysis. Psychiatria Clin 1983; 16: 254-264

Angst J, Bänninger R, Nüsperli M, Scharfetter C, Stassen HH: Syndromale Gruppierungen endogener Psychosen in genetischer Sicht. In: Perspektiven der Schizophrenie-Forschung, ed: Pflug B., Foerster K., Straube E.; Fischer, Stuttgart New York, 1985: 25-38

Stassen HH, Bomben G, Propping P: Genetic aspects of the EEG: an investigation into the within-pair similarity of monozygotic and dizygotic twins with a new method of analysis. Electroenceph clin Neurophysiol 1987; 66: 489-501

Stassen HH, Scharfetter C, Angst J: Morbid risks of subgroups of affective disorders: some methodological and empirical results. J Psychiat Research 1987; 21: 347-355

Stassen HH, Scharfetter C, Winokur G, Angst J: Familial syndrome patterns in schizophrenia, schizoaffective disorder, mania and depression. Eur Arch Psychiatr Neurol Sci 1988; 237: 115-123

Stassen HH, Lykken DT, Bomben G: The within-pair similarity of twins reared apart. Eur Arch Psychiatr Neurol Sci 1988; 237: 244-252

Stassen HH, Lykken DT, Propping P, Bomben G: Genetic determination of the human EEG (survey of recent results from twins reared together and apart). Human Genetics 1988; 80: 165-176

Angst J, Stassen HH, Woggon B: Effect of neuroleptics on positive and negative symptoms and the deficit state. Psychopharmacology 1989; 99: 41-46

Angst J, Stassen HH, Gross G, Huber G, Stone MH: Suicide in affective and schizoaffective disorders. In: Marneros A. and Tsuang M.T. (eds) Affective and Schizoaffective disorders. Springer, Berlin-Heidelberg 1990: 168-185

Stassen HH, Schmid GB, Gross G, Angst J, Huber G: Prädiktoren des langfristigen Verlaufs schizophrener Erkrankungen. In: G. Huber (ed), Idiopathische Psychosen: Psychopathologie, Neurologie, Therapie. Schattauer, Stuttgart-New York, 1990: 95-104

Angst J, Delini-Stula A, Stabl M, Stassen HH: Is a cutoff score a suitable measure of treatment outcome in short-term trials in depression? A methodological meta-analysis. Human Psychopharmacology 1993; 8: 311-317

Stassen HH, Lykken DT, Propping P: Zwillingsuntersuchungen zur Genetik des normalen Elektroenzephalogramms. In: P. Baumann (ed): Biologische Psychiatrie der Gegenwart, Wien: Springer 1993, 139-144

Kaprio J, Buchsbaum M, Gottesman II, Heath A, Körner J, Kringlen E, McGuffin P, Propping P, Rietschel M, Stassen HH: What can twin studies contribute to the understanding of adult psychopathology? In: T.J. Bouchard jr. and P. Propping: Twins as a tool for behavioral genetics. Chichester: John Wiley & Sons, Dahlem Workshop Reports, Life Sciences Research Report 1993; 53: 287-299

Kuny S, Stassen HH: Speaking behavior and voice sound characteristics in depressive patients during recovery. J Psychiat Research 1993; 27,3: 289-307

Stassen HH, Delini-Stula A, Angst J: Time course of improvement under antidepressant treatment: a survival-analytical approach. Eur Neuropsychopharmacol 1993; 3: 127-135

Stassen HH, Angst J, Delini-Stula A: Severity at baseline and onset of improvement in depression. Meta-analysis of Imipramine and Moclobemide vs Placebo. Eur Psychiatry 1994; 9: 129-136

Stassen HH, Angst J: Methods of estimating onset of improvement. Eur Neuropsychopharma­cology 1994; 4,3: 284-285

Stassen HH, Albers M, Püschel J, Scharfetter C, Tewesmeier M, Woggon B: Speaking behavior and voice sound characteristics associated with negative schizophrenia. J Psychiat Research 1995; 29,4: 277-296

Stassen HH (1995) Affekt und Sprache. Stimm- und Sprachanalysen bei Gesunden, depressiven und schizophrenen Patienten. Monographien aus dem Gesamtgebiete der Psychiatrie, Bd. 79. Berlin, Heidelberg: Springer

Scharfetter C, Stassen HH: Psychopathological concepts. Psychopathology 1995; 28: 8-12

Kuny S, Stassen HH: Cognitive performance in patients recovering from depression. Psychopathology 1995; 28: 190-207

Stassen HH, Angst J, Delini-Stula A: Delayed onset of action of antidepressant drugs? Survey of results of Zurich meta-analyses. Pharmacopsychiatry 1996; 29: 87-96

Dünki RM, Schmid GB, Scheidegger P, Stassen HH, Bomben G, Propping P: Reliable computer-assisted classification of the EEG: EEG variants in index cases and their first-degree relatives. Am J Med Genetics B 1996; 67,1: 1-8

Stassen HH, Ragaz M, Reich T: Age-of-onset or age-cohort changes in the lifetime occurrence of depression? Psychiat Genetics 1997; 7: 27-34

Stassen HH, Angst J, Delini-Stula A: Delayed onset of action of antidepressant drugs? Survey of results of Zurich meta-analyses. Eur Psychiatry 1997; 12: 166-176

Kuny S, Stassen HH, Hell D (1997) Kognitive Beeinträchtigungen in der Depression. Schweiz Arch Neurol Psychiatrie 150,3: 18-25

Angst J, Stassen HH: Methodische Probleme der Prüfung von Antidepressiva. In: Stieglitz RD, Fähndrich E, Möller HJ (eds): Syndromale Diagnostik psychischer Störungen. Hogrefe, Göttingen 1998: 5-12

Stassen HH, Angst J, Delini-Stula A: Onset of improvement under fluoxetine and moclobemide. Eur Psychiatry 1998; 13,3: 128-133

Stassen HH, Kuny S,. Hell D: The speech analysis approach to determining onset of improvement under antidepressants. Eur Neuropsychopharmacology 1998; 8,4: 303-310

Püschel J, Stassen HH, Bomben G, Scharfetter C, Hell D: Speaking behavior and voice sound characteristics in acute schizophrenia. J Psychiat Research 1998; 32: 89-97

Stassen HH, Bomben G, Hell D: Familial brain wave patterns: study of a 12 sib family. Psychiat Genetics 1998; 8: 141-153

Angst J, Angst F, Stassen HH: Suicide risk in patients with major depressive disorder. J Clin Psychiatry 1999; 60,2: 57-62

Stassen HH, Angst J, Delini-Stula A: Fluoxetine versus moclobemide: cross-comparison between the time course of improvement. Pharmacopsychiatry 1999; 32: 56-60

Stassen HH, Begleiter H, Porjesz B, Rice J, Scharfetter C, Reich T: Structural decomposition of genetic diversity in families with alcohol dependence. Genetic Analysis Workshop 11: Analysis of genetic and environmental factors in common diseases. Genetic Epidemiology 1999; 17: 325-330

Stassen HH, Coppola R. Torrey EF, Gottesman II, Kuny S, Rickler KC, Hell D: EEG differences in monozygotic twins discordant and concordant for schizophrenia. Psychophysiology 1999; 36,1: 109-117

Stassen HH and Scharfetter C: Integration of genetic maps by polynomial transformations. Am J Med Genetics B 2000; 96: 108-113

Stassen HH, Bridler R, Hägele S, Hergersberg M, Mehmann B, Schinzel A, Weisbrod M, Scharfetter C: Schizophrenia and smoking: evidence for a common neurobiological basis? Am J Med Genetics B 2000; 96: 173-177

Dünki RM, Schmid GB, Stassen HH: Intraindividual specificity and stability of the human EEG: Linear vs. nonlinear approaches. Meth Inform Med 2000; 39: 78-82

Hoffmann K, Stassen HH, Reis A: Genkartierung in Isolatpopulationen. Medizinische Genetik 2000; 12,4: 428-437

Stassen HH, Scharfetter C: Oligogenic approaches to the predisposition of asthma in ethnically diverse populations. Genetic Analysis Workshop 12: Analysis of genetic and environmental factors in common diseases. Genetic Epidemiology 2001; 21(1): 284-289

Angst F, Stassen HH, Clayton PJ, Angst J: Mortality of patients with mood disorders: follow-up over 34 to 38 years. J Aff Disorders 2002; 68: 167-181

Montgomery SA, Bech P, Blier P, Moller HJ, Nierenberg AA, Pinder RM, Quitkin FM, Reimitz PE, Rosenbaum JF, Rush AJ, Stassen HH, Thase ME: Selecting methodologies for the evaluation of differences in time to response between antidepressants. J Clin Psychiatry 2002; 63(8): 694-699

Lott PR, Guggenbühl S, Schneeberger A, Pulver AE, Stassen HH: Linguistic analysis of the speech output of schizophrenic, bipolar, and depressive patients. Psychopathology 2002; 35(4): 220-227

Stassen HH, Angst J (2002) Wirkung und Wirkungseintritt in der Antidepressiva-Behandlung. In: Böker H and Hell D (eds) Therapie der affektiven Störungen. Stuttgart und New York: Schattauer 141-165

Umbricht D, Koller R, Schmid L, Skrabo A, Grübel C, Huber T, Stassen HH: How specific are deficits in mismatch negativity generation to schizophrenia? Biol Psychiatry 2003; 53: 1120-1131

Stassen HH, Hoffmann K, Scharfetter C: Similarity by state/descent and genetic vector spaces: Analysis of a longitudinal family study. Genetic Analysis Workshop 13: Analysis of longitudinal family data for complex diseases and related risk factors. BMC Genet 2003; 4, S59: 1-6

Stassen HH: EEG and evoked potentials. In: D. Cooper (ed) Nature Encyclopedia of the Human Genome. Nature Publishing Group, London 2003; 3: 266-269

Stassen HH, Bridler R, Hell D, Weisbrod M, Scharfetter C: Ethnicity-independent genetic basis of functional psychoses. A Genotype-to-phenotype approach. Am J Med Genetics B 2004; 124: 101-112

Weisbrod M, Hill H, Sauer H, Niethammer R, Guggenbühl S, Stassen HH: Nongenetic pathologic developments of brain-wave patterns in monozygotic twins discordant and concordant for schizophrenia. Am J Med Genetics B 2004; 125: 1-9

Stassen HH, Begleiter H, Beirut L, Culverhouse R, Hinrichs T, Porjesz B, Rice J, Scharfetter C, Reich T: Oligogenic approaches to the predisposition of alcohol dependence. A genome-wide search on 255 families. Neurol Psychiat Brain Res 2004; 11: 13-22

Scharfetter C, Kurz T, Hoffmann K, Deichmann KA, Stassen HH: Oligogenic approaches to the predisposition of atopy in ethnically diverse populations. Analysis of a multinational sample. Neurol Psychiat Brain Res 2004; 11: 27-36

Stassen HH (2004) Veränderungen der Sprechmotorik. In: T.Jahn (ed) Bewegungsstörungen bei psychischen Erkrankungen. Springer Heidelberg: 107-125

Szegedi A, Rujescu D, Tadic A, Matthias J. Mueller MJ, Ralf Kohnen R, Stassen HH, Dahmen N: The catechol-O-methyltransferase Val108/158Met-polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in Major Depression. Pharmacogenomics 2005; 5(1): 49-53

Kurz T, Altmueller J, Strauch K, Rueschendorf F, Heinzmann A, Moffatt MF, Cookson W, Inacio F, Nuernberg P, Stassen HH, Deichmann KA: A genome-wide screen on the genetics of atopy in a multiethnic European population reveals a major atopy locus on chromosome 3q21.3. Allergy, Eur J of Allergy and Clinical Immunology 2005; 60(2): 192-199

Angst J, Sellaro R, Stassen HH, Gamma A: Diagnostic conversion from depression to bipolar disorders: results of a long-term prospective study of hospital admissions. J Aff Disorders 2005; 84(2-3): 149-157

Lavergne F, Berlin I, Gamma A, Stassen H, Angst J: Onset of improvement and response to mirtazapine in depression: a multicenter naturalistic study of 4771 patients. Neuropsychiatric Disease and Treatment 2005; 1(1): 59-68

Berger M, Stassen HH, Köhler K, Krane V, Mönks D, Wanner C, Hoffmann K, Hoffmann MM, Zimmer M, Bickeböller H, Lindner TH: Hidden population substructures in an apparently homogeneous population bias association studies. Eur J Hum Genetics 2006; 14: 236-244

Buckelmüller J, Landolt HP, Stassen HH, Achermann P: Trait-like individual differences in the human sleep EEG. Neuroscience 2006; 138: 351-356

Stassen HH, Scharfetter C: Vulnerability, resilience and response to psychotropic drugs: shared genetic factors? Am J Med Genetics 2006; 141: 707-708

Stassen HH, Szegedi A, Scharfetter C: Modeling Activation of Inflammatory Response System. A Molecular-Genetic Neural Network Analysis. BMC Proceedings 2007, 1 (Suppl 1): S61, 1-6

Tadic A, Rujescu D, Muller MJ, Kohnen R, Stassen HH, Dahmen N, Szegedi A: A monoamine oxidase B gene variant and short-term antidepressant treatment response. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31(7): 1370-1377

Tadic A, Muller MJ, Rujescu D, Kohnen R, Stassen HH, Dahmen N, Szegedi A: The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. Am J Med Genet B Neuropsychiatr Genet. 2007; 144(3): 325-331

Stassen HH, Angst J, Scharfetter C, Szegedi A: What lets patients under antidepressants get stuck in their recovery after initial improvement? Eur Neuropsychopharmacol. 2007; 17 (Suppl. 4): S344-345

Stassen HH, Hell D, Hoffmann K, Scharfetter C, Szegedi A: Linking Autoantibody Formation to Genetic Vulnerability to Psychiatric Disorders. Normative Rheumatoid Arthritis Study of 1,042 subjects genotyped for 5,728 SNPs. Am J Med Genetics B, Neuropsychiatr Genet (2007: in preparation)

Stassen HH, Angst J, Hell D, Scharfetter C, Szegedi A: Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. J Clin Psychiatry 2007; 68(8): 1195-1205

Tadic A, Rujescu D, Dahmen N, Stassen HH, Muller MJ, Kohnen R, Szegedi A: Association Analysis between Variants of the Interleukin-1? and the Interleukin-1 Receptor Antagonist Gene and Antidepressant Treatment Response in Major Depression. Neuropsychiatr Dis Treat 2008; 4(1): 269-276

Szegedi A, Jansen WT, Van Willigenburg AP, Van der Meulen E, Stassen HH, Thase ME: Early improvement as a predictor of treatment outcome in patients with major depressive disorder: Why the first 2 weeks really matter —evidence from 6562 patients. J Clin Psychiatry 2009; 70(3): 344-353

Stassen HH, Hoffmann K, Scharfetter C: The Difficulties of Reproducing Conventionally Derived Results through 500k-Chip Technology. BMC Genet Proc. 2009; 3 Suppl 7: S66

Hoffmann K, Planitz C, Rüschendorf F, Müller-Myhsok B, Stassen HH, Lucke B, Mattheisen M, Stumvoll M, Bochmann R, Zschornack G, Wienker TF, Nürnberg P, Reis A, Luft FC, Lindner TH: A novel locus for arterial hypertension on chromosome 1p36 maps to a metabolic syndrome trait cluster in the Sorbs, a Slavic population isolate in Germany. J Hypertens 2009; 27: 983-990

Stassen HH, Anghelescu IG, Braun S, Hoffmann K, Rujescu D, Scharfetter C, Szegedi A, Tadic A: Vulnerability to major psychiatric disorders, response to treatment and medical comorbidity — shared genetic factors? Eur Neuropsychopharmacol. 2009; 19 (Suppl. 3): 262

Lötscher K, Stassen HH, Hell D, Bridler R: Community-based crisis home programme — cost-efficient alternative to psychiatric hospitalization. Nervenarzt 2009; 80(7): 818-826

Gravemann S, Schnipper N, Meyer H, Vaya A, Nowaczyk MJM, Rajab A, Hofmann WK, Salewsky B, Tönnies H, Neitzel H, Stassen HH, Sperling K, Hoffmann K. Dosage effect of zero to three functional LBR-genes in vivo and in vitro. Nucleus 2010; 1(2): 1-12

Lötscher K, Anghelescu IG, Braun S, Bridler R, Stassen HH: Polypharmacy in psychiatry: clinical practice versus empirical evidence. Eur Neuropsychopharmacol. 2010; 20 (Suppl. 3): 378-379

Kemp DE, Ganocy SJ, Brecher M, Carlson BX, Edwards S, Eudicone JM, Evoniuk G, Jansen W, Leon AC, Minkwitz M, Pikalov A, Stassen HH, Szegedi A, Tohen M, Van Willigenburg AP, Calabrese JR: Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. J Affect Disord. 2011; 130(1-2): 171-179

Giegling I, Drago A, Schäfer M, Hartmann AM, Sander T, Toliat MR, Möller HJ, De Ronchi D, Stassen HH, Rujescu D, Serretti A: Lack of association between 71 variations located in candidate genes and response to acute haloperidol treatment. Psychopharmacology 2011; 214(3): 719-728

Giegling I, Drago A, Dolzan V, Plesnicar BK, Schäfer M, Hartmann AM, Sander T, Toliat MR, Möller HJ, Stassen HH, Rujescu D, Serretti A: Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol. Pharmacogenet Genomics. 2011; 21(4): 206-216

Stassen HH, Anghelescu IG, Angst J, Böker H, Lötscher K, Rujescu D, Szegedi A, Scharfetter C: Predicting Response to Psychopharmacological Treatment. Survey of Recent Results. Pharmacopsychiatry 2011; 44: 263-272